Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptides.

  title={Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptides.},
  author={Marguerite H. Payne and John L Krstenansky and Mark T. Yates and Simon J. T. Mao},
  journal={Journal of medicinal chemistry},
  volume={34 3},
C-Terminal fragment analogues of the leech protein hirudin or the related protein hirudin PA block thrombin's cleavage of fibrinogen. Three series of synthetic peptides were synthesized to study the effects of sulfation in hirudin-derived peptides. Potency of hirudin analogues increased with p-(amino)Phe63, p-(aminosulfonate)Phe63, and p-(sulfate)Tyr63 substitution in place of Tyr63. Sulfation of Tyr56, which in hirudin is normally Phe, resulted in a loss of 1 order of magnitude in potency. The… 
6 Citations
Structure-activity studies on C-terminal hirudin peptides containing sulfated tyrosine residues.
Based on the analysis of structure-activity relationships of these sulfated peptides for thrombin inhibition, the Tyr62 and Tyr63 bisulfated peptide GDFEEIPEY(SO3H)Y(SO 3H)LQ was found to be the most potent inhibitor of throm bin among the products tested.
Synthesis of a New Bivalent Hirudin Analog (hirufos), which includes a stable 4′‐phosphono‐L‐phenylalanine mimic of (L‐tyrosine O4‐sulfate)‐63
The synthesis on solid phase of a new derivative of the anticoagulant protein hirudin is described (see Scheme and Fig.1, I). The henicosapeptide is a bivalent conjugate of the C-terminus of hirudin
Tyrosine sulfation of the glycoprotein Ib-IX complex: identification of sulfated residues and effect on ligand binding.
Here, we present evidence that glycoprotein (GP) Ib alpha, one of three polypeptides that make up the GP Ib--IX complex--the receptor for von Willebrand factor (vWf) on the surface of unactivated
Current status of the anticoagulant hirudin: its biotechnological production and clinical practice
Hirudin may expand its therapeutic utility over heparin in the near future after 10 years of clinical applications and two recombinant hirudins and a hirUDin analogue have gained marketing approval from the United States Food and Drug Administration.
The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
It is proposed that the length, flexibility and different charge architecture of the VR1 loop of t-PA invoke an induced fit of the reactive center loop of PAI-1, thereby enhancing the rate of acylation in the Michaelis complex between thrombin-VR1(t-PA) and PAI -1 by more than two orders of magnitude.
The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation.
The ability of a variety of thrombin inhibitors of different type and mechanism of action of influence the activity ofThrombin after activation of the coagulation system was studied.